Contextual evidence review for the CDC guideline for prescribing opioids for chronic pain – United States, 2016
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Help
Clear All

Query Builder

Query box

Help
Clear All

For additional assistance using the Custom Query please check out our Help Page

i

Contextual evidence review for the CDC guideline for prescribing opioids for chronic pain – United States, 2016

Filetype[PDF-640.23 KB]


  • English

  • Details:

    • Journal Article:
      MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports
    • Description:
      Contextual evidence is complementary information that assists in translating the clinical research findings into recommendations. CDC conducted contextual evidence reviews on four topics to supplement the clinical evidence review findings:

      Effectiveness of non-pharmacologic (e.g., cognitive behavioral therapy [CBT], exercise therapy, interventional treatments, multimodal pain treatment) and non-opioid pharmacologic treatments (e.g., acetaminophen, non-steroidal anti-inflammatory drugs [NSAIDs], antidepressants, anticonvulsants),including studies of any duration;

      Benefits and harms of opioid therapy (including additional studies not included in the clinical evidence review, such as studies that were not restricted to patients with chronic pain, evaluated outcomes at any duration, performed ecological analyses, or used observational study designs other than cohort and case-cohort control studies) related to specific opioids, high dose therapy, co-prescription with other controlled substances, duration of use, special populations, and potential usefulness of risk stratification/mitigation approaches; in addition to effectiveness of treatments associated with addressing potential harms of opioid therapy (opioid use disorder);

      Clinician and patient values and preferences related to opioids and medication risks, benefits, and use; and

      Resource allocation including costs and economic efficiency of opioid therapy and risk mitigation strategies.

      CDC also reviewed clinical guidelines that were relevant to opioid prescribing and could complement the CDC recommendations in development (e.g., guidelines on nonpharmacologic and nonopioid pharmacologic treatments; guidelines with recommendations related to specific clinician actions such as urine drug testing or opioid tapering protocols).

    • Document Type:
    • Main Document Checksum:
    • File Type:

    Supporting Files

    • No Additional Files

    More +

    Related Documents

    You May Also Like

    Checkout today's featured content at stacks.cdc.gov